• Abbott Laboratories is preparing to report its second-quarter 2026 results after a period of advances in diagnostics and medical devices, including its cancer-focused portfolio and diabetes technologies.
• Recent progress in blood-based colorectal cancer screening through its Freenome collaboration and a global CGM partnership with Medtronic highlights Abbott’s expanding role in automated, data-driven healthcare solutions.
• We’ll now examine how the Freenome colorectal cancer screening progress could reshape Abbott’s investment narrative around diagnostics-led growth.

Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

Abbott Laboratories Investment Narrative Recap

To own Abbott today, I think you need to believe in its ability to compound cash flows from a broad, innovation-led healthcare portfolio, particularly in diagnostics and medical devices, while managing pricing and reimbursement pressures. The latest Freenome blood-based colorectal cancer data is an incremental positive for diagnostics, but the near term story still looks most sensitive to execution in medical devices and any margin pressure from tariffs, FX and competitive pricing in diabetes and diagnostics.

Among recent announcements, the Freenome SimpleScreen CRC validation results stand out as most relevant here, because they directly support the idea that diagnostics, not just devices, can be a meaningful growth driver for Abbott’s mix. If commercialized successfully after FDA review, this kind of cancer screening portfolio could help offset headwinds from declining COVID testing and China procurement pressures, reinforcing the thesis that new, higher-value tests can partially counteract pricing and volume challenges elsewhere.

But while innovation helps, investors should also be aware of the mounting risks around CGM pricing and potential commoditization in diabetes, where...

Abbott Laboratories’ narrative projects $59.6 billion revenue and $9.5 billion earnings by 2029. This requires 9.7% yearly revenue growth and about a $3.2 billion earnings increase from $6.3 billion today.

Uncover how Abbott Laboratories' forecasts yield a $116.54 fair value, a 31% upside to its current price.

Exploring Other Perspectives

Five Simply Wall St Community fair value estimates cluster between US$116.54 and US$147.56, reflecting a wide spread in individual expectations. Against this, the recent focus on diagnostics-led growth and ongoing reimbursement and pricing risks gives you several different angles on how Abbott’s future performance could unfold.

Explore 5 other fair value estimates on Abbott Laboratories - why the stock might be worth as much as 66% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Abbott Laboratories research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abbott Laboratories' overall financial health at a glance.

Contemplating Other Strategies?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The latest GPUs need a type of rare earth metal called Neodymium and there are only 30 companies in the world exploring or producing it. Find the list for free.
• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.